UY38244A - AGENTES ENLAZANTES DE PSMA y SUS USOS - Google Patents
AGENTES ENLAZANTES DE PSMA y SUS USOSInfo
- Publication number
- UY38244A UY38244A UY0001038244A UY38244A UY38244A UY 38244 A UY38244 A UY 38244A UY 0001038244 A UY0001038244 A UY 0001038244A UY 38244 A UY38244 A UY 38244A UY 38244 A UY38244 A UY 38244A
- Authority
- UY
- Uruguay
- Prior art keywords
- binding agents
- psma binding
- psma
- antibodies
- fragments
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/3069—Reproductive system, e.g. ovaria, uterus, testes, prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/515—Complete light chain, i.e. VL + CL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Cell Biology (AREA)
- Reproductive Health (AREA)
- Pregnancy & Childbirth (AREA)
- Gynecology & Obstetrics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
La presente invención se refiere a anticuerpos que se unen específicamente a PSMA o PSMA y CD3, polinucleótidos que codifican los anticuerpos o fragmentos, y métodos para elaborar y usar lo anterior.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201862676099P | 2018-05-24 | 2018-05-24 |
Publications (1)
Publication Number | Publication Date |
---|---|
UY38244A true UY38244A (es) | 2019-11-29 |
Family
ID=67253934
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
UY0001038244A UY38244A (es) | 2018-05-24 | 2019-05-24 | AGENTES ENLAZANTES DE PSMA y SUS USOS |
Country Status (25)
Country | Link |
---|---|
US (1) | US11746157B2 (es) |
EP (1) | EP3802609A2 (es) |
JP (1) | JP7361727B2 (es) |
KR (1) | KR20210015902A (es) |
CN (1) | CN112513085B (es) |
AR (1) | AR116173A1 (es) |
AU (1) | AU2019274657A1 (es) |
BR (1) | BR112020023872A2 (es) |
CA (1) | CA3101272A1 (es) |
CL (1) | CL2020003031A1 (es) |
CR (1) | CR20200563A (es) |
DO (1) | DOP2020000216A (es) |
EA (1) | EA202092839A1 (es) |
EC (1) | ECSP20082991A (es) |
IL (1) | IL278888A (es) |
JO (1) | JOP20200303A1 (es) |
MA (1) | MA52777A (es) |
MX (1) | MX2020012598A (es) |
NI (1) | NI202000086A (es) |
PE (1) | PE20211916A1 (es) |
PH (1) | PH12020551997A1 (es) |
SG (1) | SG11202011633SA (es) |
TW (1) | TW202016135A (es) |
UY (1) | UY38244A (es) |
WO (1) | WO2019224718A2 (es) |
Families Citing this family (27)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP3620473A1 (en) | 2013-01-14 | 2020-03-11 | Xencor, Inc. | Novel heterodimeric proteins |
US10858417B2 (en) | 2013-03-15 | 2020-12-08 | Xencor, Inc. | Heterodimeric proteins |
US10259887B2 (en) | 2014-11-26 | 2019-04-16 | Xencor, Inc. | Heterodimeric antibodies that bind CD3 and tumor antigens |
LT3223845T (lt) | 2014-11-26 | 2021-08-25 | Xencor, Inc. | Heterodimeriniai antikūnai, kurie suriša cd3 ir cd20 |
KR20190020341A (ko) | 2016-06-28 | 2019-02-28 | 젠코어 인코포레이티드 | 소마토스타틴 수용체 2에 결합하는 이종이량체 항체 |
CN112912397A (zh) | 2018-05-24 | 2021-06-04 | 詹森生物科技公司 | 抗cd3抗体及其用途 |
AU2020259404A1 (en) | 2019-04-19 | 2021-09-23 | Janssen Biotech, Inc. | Methods of treating prostate cancer with an anti- PSMA/CD3 antibody |
US20210079115A1 (en) * | 2019-04-19 | 2021-03-18 | Janssen Biotech, Inc. | Methods of treating renal cancer with an anti- psma/cd3 antibody |
MX2021013667A (es) | 2019-05-10 | 2022-01-31 | Janssen Biotech Inc | Quelantes macrocíclicos y métodos de uso de estos. |
WO2021231976A1 (en) * | 2020-05-14 | 2021-11-18 | Xencor, Inc. | Heterodimeric antibodies that bind prostate specific membrane antigen (psma) and cd3 |
IL298342A (en) | 2020-05-20 | 2023-01-01 | Janssen Biotech Inc | Site-specific conjugation of transglutaminase-glycosylated monoclonal antibodies |
KR20230011417A (ko) | 2020-05-20 | 2023-01-20 | 얀센 바이오테크 인코포레이티드 | 글리코실화된 Fc 도메인을 포함하는 단백질의 부위 특이적 컨쥬게이션을 위한 방법 |
KR102607909B1 (ko) | 2020-08-19 | 2023-12-01 | 젠코어 인코포레이티드 | 항-cd28 조성물 |
AU2021345124A1 (en) | 2020-09-16 | 2023-03-30 | Amgen Inc. | Methods for administering therapeutic doses of bispecific T-cell engaging molecules for the treatment of cancer |
EP4243935A1 (en) | 2020-11-10 | 2023-09-20 | Janssen Biotech, Inc. | Macrocyclic compounds and methods of use thereof |
US20240059789A1 (en) * | 2021-01-28 | 2024-02-22 | Janssen Biotech, Inc. | Psma binding proteins and uses thereof |
CN116963774A (zh) * | 2021-01-28 | 2023-10-27 | 瑞泽恩制药公司 | 用于治疗细胞因子释放综合征的组合物和方法 |
AU2022232375A1 (en) | 2021-03-09 | 2023-09-21 | Xencor, Inc. | Heterodimeric antibodies that bind cd3 and cldn6 |
EP4305065A1 (en) | 2021-03-10 | 2024-01-17 | Xencor, Inc. | Heterodimeric antibodies that bind cd3 and gpc3 |
WO2022232376A1 (en) | 2021-04-29 | 2022-11-03 | Amgen Inc. | Methods for reducing low molecular weight species of recombinantly-produced proteins |
US20230073821A1 (en) * | 2021-08-27 | 2023-03-09 | International Business Machines Corporation | Antigen-binding proteins targeting coronavirus (cov) variants |
EP4429718A1 (en) | 2021-11-09 | 2024-09-18 | Janssen Biotech, Inc. | Macrocyclic compounds and diagnostic uses thereof |
CA3240194A1 (en) | 2021-11-09 | 2023-05-19 | Edward Cleator | Macrocyclic compounds and methods of making the same |
WO2023152581A1 (en) | 2022-02-09 | 2023-08-17 | Janssen Biotech, Inc. | Method of treating cancer with psmaxcd3 antibody |
WO2023183231A1 (en) | 2022-03-21 | 2023-09-28 | Amgen Inc. | Combination therapy methods with t-cell engaging molecules for treatment of prostate cancer |
WO2023198015A1 (zh) * | 2022-04-11 | 2023-10-19 | 江苏恒瑞医药股份有限公司 | 特异性结合psma和cd28的抗原结合分子及其医药用途 |
WO2024134403A1 (en) * | 2022-12-22 | 2024-06-27 | Janssen Research & Development, Llc | Methods of preparing antibody-polynucleotide conjugates |
Family Cites Families (95)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US541606A (en) | 1895-06-25 | Sealed package | ||
US4683195A (en) | 1986-01-30 | 1987-07-28 | Cetus Corporation | Process for amplifying, detecting, and/or-cloning nucleic acid sequences |
US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
WO1988001649A1 (en) | 1986-09-02 | 1988-03-10 | Genex Corporation | Single polypeptide chain binding molecules |
US5606040A (en) | 1987-10-30 | 1997-02-25 | American Cyanamid Company | Antitumor and antibacterial substituted disulfide derivatives prepared from compounds possessing a methyl-trithio group |
US5770701A (en) | 1987-10-30 | 1998-06-23 | American Cyanamid Company | Process for preparing targeted forms of methyltrithio antitumor agents |
US5223409A (en) | 1988-09-02 | 1993-06-29 | Protein Engineering Corp. | Directed evolution of novel binding proteins |
GB8823869D0 (en) | 1988-10-12 | 1988-11-16 | Medical Res Council | Production of antibodies |
IL162181A (en) | 1988-12-28 | 2006-04-10 | Pdl Biopharma Inc | A method of producing humanized immunoglubulin, and polynucleotides encoding the same |
US5208020A (en) | 1989-10-25 | 1993-05-04 | Immunogen Inc. | Cytotoxic agents comprising maytansinoids and their therapeutic use |
GB8928874D0 (en) | 1989-12-21 | 1990-02-28 | Celltech Ltd | Humanised antibodies |
US6150584A (en) | 1990-01-12 | 2000-11-21 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
US5427908A (en) | 1990-05-01 | 1995-06-27 | Affymax Technologies N.V. | Recombinant library screening methods |
US6172197B1 (en) | 1991-07-10 | 2001-01-09 | Medical Research Council | Methods for producing members of specific binding pairs |
GB9015198D0 (en) | 1990-07-10 | 1990-08-29 | Brien Caroline J O | Binding substance |
US6255458B1 (en) | 1990-08-29 | 2001-07-03 | Genpharm International | High affinity human antibodies and human antibodies against digoxin |
US20030206899A1 (en) | 1991-03-29 | 2003-11-06 | Genentech, Inc. | Vascular endothelial cell growth factor antagonists |
US6582959B2 (en) | 1991-03-29 | 2003-06-24 | Genentech, Inc. | Antibodies to vascular endothelial cell growth factor |
WO1994004679A1 (en) | 1991-06-14 | 1994-03-03 | Genentech, Inc. | Method for making humanized antibodies |
AU675916B2 (en) | 1991-06-14 | 1997-02-27 | Genentech Inc. | Method for making humanized antibodies |
ATE408012T1 (de) | 1991-12-02 | 2008-09-15 | Medical Res Council | Herstellung von autoantikörpern auf phagenoberflächen ausgehend von antikörpersegmentbibliotheken |
ATE348110T1 (de) | 1992-10-28 | 2007-01-15 | Genentech Inc | Hvegf rezeptor als vegf antagonist |
NZ258392A (en) | 1992-11-13 | 1997-09-22 | Idec Pharma Corp | Chimeric and radiolabelled antibodies to the b lymphocyte cellsurface antigen bp35 (cd-20) and their use in the treatment of b cell lymphona |
US5635483A (en) | 1992-12-03 | 1997-06-03 | Arizona Board Of Regents Acting On Behalf Of Arizona State University | Tumor inhibiting tetrapeptide bearing modified phenethyl amides |
ATE199392T1 (de) | 1992-12-04 | 2001-03-15 | Medical Res Council | Multivalente und multispezifische bindungsproteine, deren herstellung und verwendung |
US5780588A (en) | 1993-01-26 | 1998-07-14 | Arizona Board Of Regents | Elucidation and synthesis of selected pentapeptides |
US5773001A (en) | 1994-06-03 | 1998-06-30 | American Cyanamid Company | Conjugates of methyltrithio antitumor agents and intermediates for their synthesis |
IL117645A (en) | 1995-03-30 | 2005-08-31 | Genentech Inc | Vascular endothelial cell growth factor antagonists for use as medicaments in the treatment of age-related macular degeneration |
AUPO591797A0 (en) | 1997-03-27 | 1997-04-24 | Commonwealth Scientific And Industrial Research Organisation | High avidity polyvalent and polyspecific reagents |
US5712374A (en) | 1995-06-07 | 1998-01-27 | American Cyanamid Company | Method for the preparation of substantiallly monomeric calicheamicin derivative/carrier conjugates |
US5714586A (en) | 1995-06-07 | 1998-02-03 | American Cyanamid Company | Methods for the preparation of monomeric calicheamicin derivative/carrier conjugates |
DE122007000021I1 (de) | 1997-04-07 | 2007-05-24 | Genentech Inc | Anti-vefg Antibodies |
KR100856995B1 (ko) | 1997-04-07 | 2008-09-04 | 제넨테크, 인크. | 인간화 항체 및 인간화 항체의 제조 방법 |
US20020032315A1 (en) | 1997-08-06 | 2002-03-14 | Manuel Baca | Anti-vegf antibodies |
US6884879B1 (en) | 1997-04-07 | 2005-04-26 | Genentech, Inc. | Anti-VEGF antibodies |
US6670127B2 (en) | 1997-09-16 | 2003-12-30 | Egea Biosciences, Inc. | Method for assembly of a polynucleotide encoding a target polypeptide |
PT1015576E (pt) | 1997-09-16 | 2005-09-30 | Egea Biosciences Llc | Metodo para a sintese quimica completa e montagem de genes e de genomas |
US6818749B1 (en) | 1998-10-31 | 2004-11-16 | The United States Of America As Represented By The Department Of Health And Human Services | Variants of humanized anti carcinoma monoclonal antibody cc49 |
US6703020B1 (en) | 1999-04-28 | 2004-03-09 | Board Of Regents, The University Of Texas System | Antibody conjugate methods for selectively inhibiting VEGF |
PT1242438E (pt) | 1999-12-29 | 2007-02-28 | Immunogen Inc | Agentes citotóxicos compreendendo dixorrubicinas e daunorrubicinas modificadas e seu uso terapêutico |
US6596541B2 (en) | 2000-10-31 | 2003-07-22 | Regeneron Pharmaceuticals, Inc. | Methods of modifying eukaryotic cells |
JP3523245B1 (ja) | 2000-11-30 | 2004-04-26 | メダレックス,インコーポレーテッド | ヒト抗体作製用トランスジェニック染色体導入齧歯動物 |
US6995162B2 (en) | 2001-01-12 | 2006-02-07 | Amgen Inc. | Substituted alkylamine derivatives and methods of use |
EP2298809A3 (en) | 2001-07-12 | 2012-02-15 | FOOTE, Jefferson | Super humanized antibodies |
EA008379B1 (ru) | 2002-02-01 | 2007-04-27 | Ариад Джин Терапьютикс, Инк. | Фосфорсодержащие соединения и их применения |
EP3000810B1 (en) | 2002-03-13 | 2017-07-19 | Array Biopharma, Inc. | N3 alkylated benzimidazole derivative as mek inhibitor |
MXPA05012723A (es) | 2003-05-30 | 2006-02-08 | Genentech Inc | Tratamiento con anticuerpos anti-vgf. |
AU2004242845B2 (en) | 2003-05-31 | 2011-06-02 | Amgen Research (Munich) Gmbh | Human-anti-human CD3 binding molecules |
US20050106667A1 (en) | 2003-08-01 | 2005-05-19 | Genentech, Inc | Binding polypeptides with restricted diversity sequences |
WO2005044853A2 (en) | 2003-11-01 | 2005-05-19 | Genentech, Inc. | Anti-vegf antibodies |
DK2489364T3 (en) | 2003-11-06 | 2015-03-02 | Seattle Genetics Inc | Monomethylvaline compounds conjugated to antibodies |
EP2397189B1 (en) | 2003-11-14 | 2015-03-18 | Brigham and Women's Hospital, Inc. | Methods of modulating immunity |
LT2612862T (lt) | 2004-05-13 | 2017-01-25 | Icos Corporation | Chinazolinonai kaip žmogaus fosfatidilinozitol-3-kinazės delta inhibitoriai |
SI1761528T1 (sl) | 2004-06-11 | 2008-06-30 | Japan Tobacco Inc | 5-amino-2,4,7-triokso-3,4,7,8-tetrahidro-2H-pirido(2,3-D)pirimidinski derivati in sorodne spojine za zdravljenje raka |
US20060009360A1 (en) | 2004-06-25 | 2006-01-12 | Robert Pifer | New adjuvant composition |
US20060204493A1 (en) | 2004-09-02 | 2006-09-14 | Genentech, Inc. | Heteromultimeric molecules |
WO2006106905A1 (ja) | 2005-03-31 | 2006-10-12 | Chugai Seiyaku Kabushiki Kaisha | 会合制御によるポリペプチド製造方法 |
DE102005028778A1 (de) | 2005-06-22 | 2006-12-28 | SUNJÜT Deutschland GmbH | Mehrlagige Folie mit einer Barriere- und einer antistatischen Lage |
WO2007004415A1 (ja) | 2005-07-01 | 2007-01-11 | Murata Manufacturing Co., Ltd. | 多層セラミック基板およびその製造方法ならびに多層セラミック基板作製用複合グリーンシート |
WO2007110205A2 (en) | 2006-03-24 | 2007-10-04 | Merck Patent Gmbh | Engineered heterodimeric protein domains |
US20090182127A1 (en) | 2006-06-22 | 2009-07-16 | Novo Nordisk A/S | Production of Bispecific Antibodies |
US20080085886A1 (en) | 2006-08-21 | 2008-04-10 | Genentech, Inc. | Aza-benzofuranyl compounds and methods of use |
EP2626371A1 (en) | 2007-07-31 | 2013-08-14 | MedImmune, LLC | Multispecific epitope binding proteins and uses thereof |
US8748356B2 (en) | 2007-10-19 | 2014-06-10 | Janssen Biotech, Inc. | Methods for use in human-adapting monoclonal antibodies |
RU2441004C1 (ru) | 2007-12-19 | 2012-01-27 | Дженентек, Инк. | 5-анилиноимидазопиридины и способы их применения |
ES2564523T3 (es) | 2007-12-19 | 2016-03-23 | Janssen Biotech, Inc. | Diseño y generación de bibliotecas de presentación en fago por pIX de novo humanas mediante fusión con pIX o pVII, vectores, anticuerpos y métodos |
US8227577B2 (en) | 2007-12-21 | 2012-07-24 | Hoffman-La Roche Inc. | Bivalent, bispecific antibodies |
US9266967B2 (en) | 2007-12-21 | 2016-02-23 | Hoffmann-La Roche, Inc. | Bivalent, bispecific antibodies |
US8242247B2 (en) | 2007-12-21 | 2012-08-14 | Hoffmann-La Roche Inc. | Bivalent, bispecific antibodies |
US20090162359A1 (en) | 2007-12-21 | 2009-06-25 | Christian Klein | Bivalent, bispecific antibodies |
US8637542B2 (en) | 2008-03-14 | 2014-01-28 | Intellikine, Inc. | Kinase inhibitors and methods of use |
MX2011000216A (es) | 2008-07-08 | 2011-03-29 | Intellikine Inc | Inhibidores de cinasa y metodos para su uso. |
CA2738429C (en) | 2008-09-26 | 2016-10-25 | Intellikine, Inc. | Heterocyclic kinase inhibitors |
ME02485B (me) | 2008-10-01 | 2017-02-20 | Amgen Res Munich Gmbh | Bispecifično jednolančano protutijelo psmaxcd3 s međuvrsnom specifičnošću |
WO2010045340A1 (en) | 2008-10-14 | 2010-04-22 | Centocor Ortho Biotech Inc. | Methods of humanizing and affinity-maturing antibodies |
ES2708124T3 (es) | 2009-04-27 | 2019-04-08 | Oncomed Pharm Inc | Procedimiento para preparar moléculas heteromultiméricas |
TW201100543A (en) | 2009-05-27 | 2011-01-01 | Hoffmann La Roche | Tri-or tetraspecific antibodies |
CN103097417B (zh) | 2010-04-20 | 2019-04-09 | 根马布股份公司 | 含异二聚体抗体fc的蛋白及其制备方法 |
AU2011325833C1 (en) | 2010-11-05 | 2017-07-13 | Zymeworks Bc Inc. | Stable heterodimeric antibody design with mutations in the Fc domain |
BR112014002353B1 (pt) | 2011-08-01 | 2022-09-27 | Genentech, Inc | Usos de antagonistas de ligação do eixo pd-1 e inibidores de mek, composições farmacêuticas, e kit |
CA2854233C (en) | 2011-11-04 | 2020-05-12 | Zymeworks Inc. | Stable heterodimeric antibody design with mutations in the fc domain |
CA2869529A1 (en) | 2012-05-24 | 2013-11-28 | Raffaella CASTOLDI | Multispecific antibodies |
CA3182876A1 (en) | 2012-11-21 | 2014-05-30 | Janssen Biotech, Inc. | Bispecific egfr/c-met antibodies |
WO2015095392A1 (en) | 2013-12-17 | 2015-06-25 | Genentech, Inc. | Anti-cd3 antibodies and methods of use |
EP2930188A1 (en) | 2014-04-13 | 2015-10-14 | Affimed Therapeutics AG | Trifunctional antigen-binding molecule |
RU2718692C2 (ru) | 2014-05-29 | 2020-04-13 | Мэкроудженикс, Инк. | Триспецифичные связывающие молекулы, которые специфически связывают антигены множества злокачественных опухолей, и способы их применения |
CR20170079A (es) | 2014-09-05 | 2017-04-27 | Janssen Pharmaceutica Nv | Agentes de unión a cd123 y usos de estos |
EP3292222A4 (en) | 2015-05-06 | 2018-10-17 | Janssen Biotech, Inc. | Prostate specific membrane antigen binding fibronectin type iii domains |
JP7019423B2 (ja) * | 2015-05-06 | 2022-02-15 | ヤンセン バイオテツク,インコーポレーテツド | 前立腺特異的膜抗原(psma)二重特異性結合剤及びその使用 |
JOP20160154B1 (ar) * | 2015-07-31 | 2021-08-17 | Regeneron Pharma | أجسام ضادة مضاد لل psma، وجزيئات رابطة لمستضد ثنائي النوعية الذي يربط psma و cd3، واستخداماتها |
US10781264B2 (en) | 2016-02-03 | 2020-09-22 | Amgen Research (Munich) Gmbh | PSMA and CD3 bispecific T cell engaging antibody constructs |
WO2018042071A1 (en) | 2016-08-30 | 2018-03-08 | Nokia Technologies Oy | Controlling transmission of information on radio links used in aggregation |
MX2020006395A (es) | 2017-12-18 | 2020-12-03 | Janssen Biotech Inc | Radioetiquetado de polipeptidos. |
MX2020012286A (es) * | 2018-05-16 | 2021-04-28 | Janssen Biotech Inc | Metodos para tratar canceres y potenciar la eficacia de agentes terapeuticos para el redireccionamiento de celulas t. |
CN112912397A (zh) | 2018-05-24 | 2021-06-04 | 詹森生物科技公司 | 抗cd3抗体及其用途 |
-
2019
- 2019-05-21 US US16/418,328 patent/US11746157B2/en active Active
- 2019-05-21 AU AU2019274657A patent/AU2019274657A1/en active Pending
- 2019-05-21 JP JP2020565292A patent/JP7361727B2/ja active Active
- 2019-05-21 MA MA052777A patent/MA52777A/fr unknown
- 2019-05-21 MX MX2020012598A patent/MX2020012598A/es unknown
- 2019-05-21 EA EA202092839A patent/EA202092839A1/ru unknown
- 2019-05-21 JO JOP/2020/0303A patent/JOP20200303A1/ar unknown
- 2019-05-21 SG SG11202011633SA patent/SG11202011633SA/en unknown
- 2019-05-21 KR KR1020207037309A patent/KR20210015902A/ko unknown
- 2019-05-21 CR CR20200563A patent/CR20200563A/es unknown
- 2019-05-21 WO PCT/IB2019/054189 patent/WO2019224718A2/en active Application Filing
- 2019-05-21 CA CA3101272A patent/CA3101272A1/en active Pending
- 2019-05-21 EP EP19739380.4A patent/EP3802609A2/en active Pending
- 2019-05-21 PE PE2020001894A patent/PE20211916A1/es unknown
- 2019-05-21 CN CN201980049177.1A patent/CN112513085B/zh active Active
- 2019-05-21 BR BR112020023872-4A patent/BR112020023872A2/pt unknown
- 2019-05-24 AR ARP190101401A patent/AR116173A1/es unknown
- 2019-05-24 UY UY0001038244A patent/UY38244A/es unknown
- 2019-05-24 TW TW108118091A patent/TW202016135A/zh unknown
-
2020
- 2020-11-20 PH PH12020551997A patent/PH12020551997A1/en unknown
- 2020-11-22 IL IL278888A patent/IL278888A/en unknown
- 2020-11-23 CL CL2020003031A patent/CL2020003031A1/es unknown
- 2020-11-23 NI NI202000086A patent/NI202000086A/es unknown
- 2020-11-24 DO DO2020000216A patent/DOP2020000216A/es unknown
- 2020-12-22 EC ECSENADI202082991A patent/ECSP20082991A/es unknown
Also Published As
Publication number | Publication date |
---|---|
CN112513085A (zh) | 2021-03-16 |
EP3802609A2 (en) | 2021-04-14 |
MX2020012598A (es) | 2021-05-27 |
JP7361727B2 (ja) | 2023-10-16 |
KR20210015902A (ko) | 2021-02-10 |
CN112513085B (zh) | 2024-06-18 |
SG11202011633SA (en) | 2020-12-30 |
IL278888A (en) | 2021-01-31 |
AU2019274657A1 (en) | 2020-12-10 |
AR116173A1 (es) | 2021-04-07 |
US11746157B2 (en) | 2023-09-05 |
JOP20200303A1 (ar) | 2020-11-23 |
JP2021524250A (ja) | 2021-09-13 |
BR112020023872A2 (pt) | 2021-02-17 |
TW202016135A (zh) | 2020-05-01 |
EA202092839A1 (ru) | 2021-02-12 |
US20200024360A1 (en) | 2020-01-23 |
DOP2020000216A (es) | 2021-09-15 |
WO2019224718A2 (en) | 2019-11-28 |
MA52777A (fr) | 2021-04-14 |
CR20200563A (es) | 2021-05-11 |
CL2020003031A1 (es) | 2021-04-16 |
ECSP20082991A (es) | 2021-01-29 |
NI202000086A (es) | 2021-03-23 |
CA3101272A1 (en) | 2019-11-28 |
WO2019224718A3 (en) | 2020-03-05 |
PE20211916A1 (es) | 2021-09-28 |
PH12020551997A1 (en) | 2021-09-06 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
UY38244A (es) | AGENTES ENLAZANTES DE PSMA y SUS USOS | |
CO2018011364A2 (es) | Anticuerpos anti-il-33, composiciones, métodos y usos de los mismos | |
UY38245A (es) | Anticuerpos anti-cd3 y usos de estos | |
AR106583A1 (es) | Anticuerpos que se unen específicamente a pd-1, tim-3 o pd-1 y tim-3 y sus usos | |
CL2020001854A1 (es) | Anticuerpos de unión a gprc5d. | |
ECSP17083779A (es) | Agentes de unión a inmunorreceptor de células t con dominios ig y motivo de inhibición basado en tirosina de inmunorreceptor (tigit) y usos de los mismos | |
NI201800044A (es) | Anticuerpos agonísticos que se unen específicamente a cd40 humano y métodos de uso | |
UY37340A (es) | Antianticuerpos gprc5d, moléculas de unión al antígeno biespecíficas que se unen a gprc5d y cd3, y usos de estas | |
CO2021001893A2 (es) | Anticuerpos anti-gdf15, composiciones y métodos de uso | |
CO2018005436A2 (es) | Anticuerpos y fragmentos de anticuerpo para la conjugación sitio-específica | |
ECSP18095014A (es) | Proteínas de unión biespecíficas que se unen a una proteína inmunomoduladora y a un antígeno tumoral | |
AR116718A1 (es) | Proteínas de unión triespecíficas anti-cd38, anti-cd28 y anti-cd3 y métodos de uso para tratar infección vírica | |
CL2021001506A1 (es) | Anticuerpos que se unen a cd3 | |
CO2021002954A2 (es) | Anticuerpos anti-αvβ8 y composiciones y usos de los mismos | |
BR112018012344A2 (pt) | anticorpos que se ligam especificamente a hla-dr e seus usos | |
CR20190417A (es) | Anticuerpos anti-par2 y usos de los mismos referencia cruzada a solicitudes relacionadas | |
AR119393A1 (es) | Anticuerpos que se unen a nkg2d | |
CO2020006453A2 (es) | Anticuerpos anti-cxcr5 y composiciones y usos de los mismos | |
CL2020001629A1 (es) | Anticuerpos de unión a hla-a2/wt1. | |
CO2020014343A2 (es) | Anticuerpos específicos para cd3 y sus usos | |
UY36602A (es) | Variantes de protoxina-ii y métodos de uso | |
DOP2016000105A (es) | Anticuerpos anti-ccl17. | |
CO2019010164A2 (es) | Anticuerpos que se unen a steap-1 | |
AR120093A1 (es) | Anticuerpos anti-ceacam y usos de los mismos | |
AR121974A1 (es) | Agentes de unión a ilt y métodos para su uso |